Final ICER report finds lack of evidence on RA drug value vs prices

The USA’s Institute for Clinical and Economic Review, (ICER), an independent not-for-profit organization, has released a Final Evidence Report and Meeting assessing the comparative clinical effectiveness and value of targeted immune modulators (TIMs) for treatment of moderately-to-severely active rheumatoid arthritis (RA).

TIMs were evaluated alone or in combination with conventional disease-modifying anti-rheumatic drugs (DMARDs), as compared head-to-head or to conventional DMARDs alone. The review includes 11 TIMs, including two agents currently under regulatory review: the interleukin (IL)-6 inhibitor sarilumab (Kevzara, from Sanofi [Euronext: SAN] and Regeneron Nasdaq: REGN]) and the JAK inhibitor baricitinib (Olumiant, from Eli Lilly (NYSE: LLY])..